LXRX Financial Facts

Collaborative research: 27.69M
Subscription and license fees: 31K
See Full Income Statement

Current portion of deferred revenue: 78.87M
Treasury stock, at cost, 218 and 158 shares, respectively: -3.37M
See Full Balance Sheet

Lexicon Pharmaceuticals, Inc. (LXRX) Earnings

  |   Expand Research on LXRX
Next EPS Date 7/30/21 *Est. EPS Growth Rate +100.0% *Last Qtr.
Average EPS % Beat Rate +31.4% Revenue Growth Rate -100.0% *Last Qtr.
Average % Move 1-Wk after EPS -1.8% Normal Earnings Time N/A
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/6/21 Q121 N/A-$0.16 N/A N/A$1.68M N/A N/A N/A
3/10/21 Q420 -$0.04-$0.28 +$0.24$200K$110K N/A Details
10/29/20 Q320 N/A$0.26 N/A N/A$16.87M N/A N/A N/A
7/30/20 Q220 -$0.65-$0.61 -$0.04$9.2M$8.83M N/A Details
4/27/20 Q120 -$0.63-$0.69 +$0.06$7.88M$7.79M N/A Details
3/12/20 Q419 -$0.48-$0.77 +$0.29$8.73M$10.26M N/A Details
11/7/19 Q319 $1.95$0.73 +$1.22$294.45M$64.25M N/A Details
8/1/19 Q219 N/A-$0.08 N/A N/A$28.52M N/A N/A N/A